Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Windtree Therapeutics stock

WINT
US97382D3035
A2P3ZQ

Price

0.72
Today +/-
+0.02
Today %
+2.47 %
P

Windtree Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Windtree Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Windtree Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Windtree Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Windtree Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Windtree Therapeutics Stock Price History

DateWindtree Therapeutics Price
11/1/20240.72 undefined
10/31/20240.70 undefined
10/30/20240.74 undefined
10/29/20240.82 undefined
10/28/20240.87 undefined
10/25/20240.86 undefined
10/24/20240.84 undefined
10/23/20240.89 undefined
10/22/20240.90 undefined
10/21/20241.07 undefined
10/18/20240.91 undefined
10/17/20240.99 undefined
10/16/20240.69 undefined
10/15/20240.66 undefined
10/14/20240.68 undefined
10/11/20240.72 undefined
10/10/20240.70 undefined
10/9/20240.75 undefined
10/8/20240.92 undefined
10/7/20241.08 undefined

Windtree Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Windtree Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Windtree Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Windtree Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Windtree Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Windtree Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Windtree Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Windtree Therapeutics’s growth potential.

Windtree Therapeutics Revenue, EBIT and net profit per share

DateWindtree Therapeutics RevenueWindtree Therapeutics EBITWindtree Therapeutics Net Income
2029e0 undefined0 undefined-437.32 M undefined
2028e0 undefined-48.14 M undefined-383.33 M undefined
2027e0 undefined-41.11 M undefined-340.14 M undefined
2026e180.91 M undefined-36.11 M undefined-18.3 M undefined
2025e0 undefined-28.05 M undefined-63.89 M undefined
2024e0 undefined-19.89 M undefined-71.39 M undefined
20230 undefined-17.54 M undefined-20.29 M undefined
20220 undefined-21.89 M undefined-39.21 M undefined
20210 undefined-32.26 M undefined-67.64 M undefined
20200 undefined-30.32 M undefined-32.57 M undefined
2019198,000 undefined-24.89 M undefined-27.48 M undefined
20181.79 M undefined-16.2 M undefined-34.76 M undefined
20171.49 M undefined-22.55 M undefined-24.82 M undefined
20162.04 M undefined-38.04 M undefined-39.49 M undefined
2015987,000 undefined-39.83 M undefined-55.17 M undefined
20142.84 M undefined-43.26 M undefined-44.06 M undefined
2013388,000 undefined-44.51 M undefined-45.22 M undefined
2012195,000 undefined-37.82 M undefined-37.32 M undefined
2011582,000 undefined-24.51 M undefined-20.97 M undefined
20100 undefined-25.53 M undefined-19.18 M undefined
20090 undefined-29.2 M undefined-29.87 M undefined
20084.6 M undefined-38.39 M undefined-39.11 M undefined
20070 undefined-39.95 M undefined-40.01 M undefined
20060 undefined-42.1 M undefined-46.33 M undefined
2005134,000 undefined-59.3 M undefined-58.9 M undefined
20041.21 M undefined-37.91 M undefined-46.2 M undefined

Windtree Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000001111000400000202110000000180000
------------------------50.00------------
----------------------100.00-------------
000000000000000000-100020000000000000
-3-2-3-9-16-5-11-11-18-24-37-59-42-39-38-29-25-24-37-44-43-39-38-22-16-24-30-32-21-17-19-28-36-41-480
--------1,100.00-1,800.00-2,400.00-3,700.00----950.00------2,150.00--1,900.00-2,200.00-1,600.00--------20.00---
-3-2-3-9-15-4-10-11-17-24-46-58-46-40-39-29-19-20-37-45-44-55-39-24-34-27-32-67-39-20-71-63-18-340-383-437
--33.3350.00200.0066.67-73.33150.0010.0054.5541.1891.6726.09-20.69-13.04-2.50-25.64-34.485.2685.0021.62-2.2225.00-29.09-38.4641.67-20.5918.52109.38-41.79-48.72255.00-11.27-71.431,788.8912.6514.10
00000000000000000000000000.010.020.030.043.88000000
------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Windtree Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Windtree Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                           
0.13.851.7511.254.023.5518.8716.719.1529.4232.0150.2626.453.0124.7915.7410.2110.1926.8986.2844.7138.725.591.8225.1522.5816.9322.356.174.32
0000000000000000000670000000000
000000000000000000000000000000
0000057500000000000019511227000000000
00.110.080.190.20.070.151.580.330.671.331.20.570.610.630.230.290.440.720.780.822.071.610.420.511.281.191.141.211.06
0.13.961.8311.444.224.1919.0218.2819.4830.0933.3451.4726.9753.6225.4215.9710.510.6327.8187.2445.5640.797.192.2425.6523.8618.1223.497.385.38
00.020.090.180.330.430.70.821.232.414.064.324.797.075.974.673.472.291.741.661.641.041.050.890.82.191.843.392.121.63
000000000000000000000000000000
00000001971951921900000000000000000000
00000000000000000000000077.0977.0977.0932.0725.2525.25
00000000000000000000000015.6815.6815.6815.683.060
0000.030.020.0200.770.160.020.040.222.642.061.510.760.570.40.40.420.32.541.450.230.170.150.150.150.150.15
00.020.090.210.340.440.71.791.582.634.34.547.439.137.475.434.042.692.142.081.943.582.511.1193.7595.1194.7751.330.5827.03
0.13.981.9211.664.574.6319.7220.0621.0632.7137.6356.0134.462.7432.8921.414.5413.3229.9489.3247.544.389.73.35119.4118.98112.8874.7937.9532.41
                                                           
2.4910.6810.850.012.282.490.020.030.030.040.050.060.070.10.10.010.010.030.040.090.090.010.0100.030.040.020.0300.01
00021.4629.7233.7160.5472.987.37122.41167.17239.8265.6330341.29361.62385.52401.71455.4541.42546.18590.49592.88616.25728.78763.07790.28830.23837.6851.26
-3.98-6.8-9.08-12.66-28.51-33.09-43.99-55.14-72.58-96.86-143.06-201.97-248.3-288.3-327.41-357.28-376.46-397.42-434.74-479.95-524.01-579.18-618.67-637.11-657.65-685.12-717.69-785.32-824.53-844.82
0-236-181019073721770-3-204210000000000000-10
000000000000000000000000000000
-1.483.641.598.813.523.1116.6517.861525.5924.1537.8917.3841.8413.994.359.084.3220.7161.5622.2511.32-25.78-20.8771.1777.9972.6144.9413.076.44
1.390.140.210.571.090.432.381.753.014.217.977.541.630.762.111.291.691.111.171.430.350.371.813.053.421.711.160.690.250.81
0.190.20.120000000004.327.095.313.453.292.974.164.796.127.27.614.26.473.984.623.941.962.05
000001.040000000003.192.4776.315.561.33.53.974.512.771.970000.9
00000000000000010.46000000007.970.160.350.290.250.23
000000.020.020.040.192.820.8510.072.022.632.440.60.140.070.070.070.06000000000
1.580.340.330.571.091.482.41.793.27.038.8217.617.9710.479.8718.997.5811.1511.711.867.8311.0713.3911.7620.637.826.134.922.464
000000.050.030.031.710.717.583.3211.5912.6211.220.430.30.220.1518.4220.32525151519.6117.42151515
00000000000000000000000015.4815.8216.787.115.065.06
0000.24000.850.621.390.670.130.240.520.870.870.690.630.690.440.540.170.040.140.510.180.7935.875.424.96
0000.2400.050.880.653.11.387.723.5612.1113.4912.091.120.940.910.5918.9620.4725.0425.1415.5130.6536.2237.227.9925.4925.02
1.580.340.330.81.091.523.282.446.38.4116.5421.1720.0823.9621.9620.118.5112.0612.2930.8228.336.1138.5327.2751.2844.0443.3332.9127.9429.01
0.13.981.929.624.64.6419.9320.321.33440.6959.0637.4565.835.9424.4617.5916.383392.3750.5547.4312.756.4122.45122.03115.9477.8441.0135.46
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Windtree Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Windtree Therapeutics's financial health and stability.

Assets

Windtree Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Windtree Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Windtree Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Windtree Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-3-2-3-9-15-4-10-11-17-24-46-58-46-40-39-29-19-20-37-45-44-55-39-18-20-27-32-67-39
00000000000012211110000000000
000000000000000000000000000-9-1
0000003-14030-110-2-1000-14200-6-10-1
0024801000807652-4-2233163-35985322
00000000000010002000210100000
00000000000000000000000000000
-2-20-4-6-4-5-12-13-23-33-57-39-29-31-27-24-22-32-40-41-33-33-21-15-24-25-23-19
000000000-1-2-1-1-3000000000000000
0-3-13622-11-119-5-11-1913200000000-1313000
0-3-13722-10-1210-303-1613200000000-1313000
00000000000000000000000000000
00000000114400-2-2-900290-50163821-3-3-1
0618003211114333472175862027225070032010020324
26180032110163539761759418182250100027017382119293
10000000000000000000000000210
00000000000000000000000000000
0041-423-3420017-2010-14-7-501659-41-5-33-3911-55-16
-2.99-2.51-1.55-5.09-7.01-4.25-6.81-12.9-14.31-24.97-35.55-58.73-41.28-33.17-32.38-27.57-24.37-22.81-33.52-41.06-41.95-33.96-33.87-21.07-15.78-24.85-25.61-23.94-19.46
00000000000000000000000000000

Windtree Therapeutics stock margins

The Windtree Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Windtree Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Windtree Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Windtree Therapeutics's sales revenue. A higher gross margin percentage indicates that the Windtree Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Windtree Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Windtree Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Windtree Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Windtree Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Windtree Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Windtree Therapeutics Margin History

Windtree Therapeutics Gross marginWindtree Therapeutics Profit marginWindtree Therapeutics EBIT marginWindtree Therapeutics Profit margin
2029e100 %0 %0 %
2028e100 %0 %0 %
2027e100 %0 %0 %
2026e100 %-19.96 %-10.11 %
2025e100 %0 %0 %
2024e100 %0 %0 %
2023100 %0 %0 %
2022100 %0 %0 %
2021100 %0 %0 %
2020100 %0 %0 %
2019100 %-12,572.22 %-13,876.26 %
2018100 %-905.76 %-1,943.85 %
2017100 %-1,518.38 %-1,671.11 %
2016100 %-1,862.68 %-1,933.89 %
20155.88 %-4,035.87 %-5,589.67 %
20145.78 %-1,525.86 %-1,554.07 %
2013-33.25 %-11,471.13 %-11,653.35 %
2012-747.18 %-19,394.36 %-19,135.9 %
2011100 %-4,211.68 %-3,602.23 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %-834.65 %-850.13 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %-44,250 %-43,958.21 %
2004100 %-3,135.32 %-3,821.59 %

Windtree Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Windtree Therapeutics earnings per share therefore indicates how much revenue Windtree Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Windtree Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Windtree Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Windtree Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Windtree Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Windtree Therapeutics Revenue, EBIT and net profit per share

DateWindtree Therapeutics Sales per ShareWindtree Therapeutics EBIT per shareWindtree Therapeutics Earnings per Share
2029e0 undefined0 undefined-14.87 undefined
2028e0 undefined0 undefined-13.04 undefined
2027e0 undefined0 undefined-11.57 undefined
2026e6.15 undefined0 undefined-0.62 undefined
2025e0 undefined0 undefined-2.17 undefined
2024e0 undefined0 undefined-2.43 undefined
20230 undefined-4.53 undefined-5.24 undefined
20220 undefined-625.4 undefined-1,120.23 undefined
20210 undefined-1,173.09 undefined-2,459.49 undefined
20200 undefined-1,742.36 undefined-1,871.61 undefined
201916.36 undefined-2,057.27 undefined-2,270.66 undefined
20181,051.76 undefined-9,526.47 undefined-20,444.71 undefined
20173,712.5 undefined-56,370 undefined-62,040 undefined
201610,210 undefined-190,180 undefined-197,450.02 undefined
20159,870 undefined-398,340 undefined-551,700 undefined
201428,350 undefined-432,580 undefined-440,580 undefined
20133,880 undefined-445,080 undefined-452,150 undefined
20121,950 undefined-378,190 undefined-373,150 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

Windtree Therapeutics business model

Windtree Therapeutics is an emerging biotechnology company based in Pittsburgh, Pennsylvania. The company was founded in 2011 and specializes in the development of innovative therapies for respiratory diseases. Windtree Therapeutics aims to improve the lives of millions of people worldwide by providing effective and safe medications. History: Windtree Therapeutics has a history that dates back to 1990 when it was founded as Advanced Inhalation Research, focusing on the development of therapies for respiratory diseases. After several rounds of financing and mergers, the company was eventually revived as Windtree Therapeutics. Since then, the company has developed and marketed a range of innovative therapies that improve the lives of millions of patients with respiratory diseases. Business model: Windtree Therapeutics is a biotechnology company focused on the development and commercialization of therapies for respiratory diseases. The company has a strong ethos for innovation and works closely with leading medical and scientific experts to develop high-quality and safe products. The company holds a variety of patents and unique technologies that allow it to improve its competitive position in the industry. Segments: Windtree Therapeutics operates in two business segments: PneumRX® Bronchial Tubes and KL4-Surfactant Technology. PneumRX® Bronchial Tubes: One of Windtree Therapeutics' main segments is the PneumRX® Bronchial Tube technology. This technology aims to improve the lives of patients with chronic obstructive pulmonary disease (COPD). The PneumRX® tubes are used as minimally invasive procedures to open the lumen of the bronchial tubes and facilitate breathing. The technology has already been used in thousands of patients worldwide and is highly regarded by physicians. KL4-Surfactant Technology: Windtree Therapeutics is also known for its KL4-Surfactant Technology, which aims to treat respiratory distress syndrome in newborns. The company has already conducted a number of clinical studies, and the results have been very promising. The KL4-Surfactant Technology is considered one of the most promising treatment options for respiratory problems in newborns. Products: Windtree Therapeutics has a range of products on the market, including: Aer-OS Nitric Oxide Inhalation Device: The Aer-OS Nitric Oxide Inhalation Device is a medical device for patients with pulmonary hypertension. It is the first and only portable nitric oxide inhalation device approved for use at home and on-the-go. The device is used to facilitate breathing and improve patients' quality of life. PneumRX® Bronchial Tubes: The PneumRX® Bronchial Tube technology has already been performed in thousands of patients and is highly regarded by physicians. The technology aims to open the lumen of the bronchial tubes and facilitate breathing. The procedures are minimally invasive and result in minimal injuries. Patients often experience significant improvement in their breathing and overall well-being. KL4-Surfactant Technology: Windtree Therapeutics' KL4-Surfactant Technology is a promising treatment option for respiratory problems in newborns. The technology aims to stimulate lung growth and facilitate breathing. The results of clinical studies have been very promising, and the treatment is considered one of the most promising treatment options for respiratory problems in newborns. In conclusion, Windtree Therapeutics is an emerging biotechnology company with a strong ethos for innovation and the development of therapies for respiratory diseases. The PneumRX® Bronchial Tube technology and KL4-Surfactant Technology are two of the company's main segments. Both technologies are promising and have the potential to improve the lives of millions of patients worldwide. Windtree Therapeutics is one of the most popular companies on Eulerpool.com.

Windtree Therapeutics SWOT Analysis

Strengths

Windtree Therapeutics Inc is focused on developing innovative therapeutics that target significant unmet medical needs. This commitment to innovation enhances their competitive advantage and potential for market success.

Windtree Therapeutics Inc holds a portfolio of robust intellectual property rights that protect their novel therapies from competitors, enabling them to maintain market exclusivity and generate revenue.

With a highly skilled and experienced management team, Windtree Therapeutics Inc is well-positioned to lead the development and commercialization of their therapeutic products. The team's expertise ensures efficient decision-making and strategic planning.

Weaknesses

Windtree Therapeutics Inc currently has limited financial resources, which may restrict their ability to fully exploit market opportunities, conduct extensive research, or effectively compete with well-funded pharmaceutical companies.

In comparison to larger pharmaceutical companies, Windtree Therapeutics Inc has a relatively small market presence, which can pose challenges in terms of brand recognition, market share, and negotiating power with distributors and healthcare providers.

Opportunities

As the healthcare industry continues to evolve and new medical needs emerge, there is a growing market demand for innovative therapeutics. Windtree Therapeutics Inc can seize this opportunity by leveraging their expertise to develop and deliver effective solutions.

Forming strategic partnerships with larger pharmaceutical companies or research institutions would provide Windtree Therapeutics Inc with additional resources, expertise, and access to established distribution networks, facilitating market entry and expansion.

Threats

The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies vying for market share. Windtree Therapeutics Inc faces the threat of competitors with substantial resources and advanced research capabilities.

The development and commercialization of therapeutic products are subject to stringent regulatory processes and approvals. Windtree Therapeutics Inc must navigate these challenges and ensure compliance with regulatory frameworks to bring their products to market.

Windtree Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Windtree Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Windtree Therapeutics shares outstanding

The number of shares was Windtree Therapeutics in 2023 — This indicates how many shares 3.876 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Windtree Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Windtree Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Windtree Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Windtree Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Windtree Therapeutics stock splits

In Windtree Therapeutics's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Windtree Therapeutics.

Windtree Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-8.27 -20.91  (-152.79 %)2024 Q2
12/31/2023-0.96 -0.74  (22.82 %)2023 Q4
9/30/2023-0.64 -0.86  (-33.83 %)2023 Q3
6/30/2023-0.69 -1.64  (-136.45 %)2023 Q2
3/31/2023-0.57 -4.76  (-733.33 %)2023 Q1
9/30/2022-13.26 -6.5  (50.98 %)2022 Q3
6/30/2022-9.18 -10  (-8.93 %)2022 Q2
3/31/2022-15.3 -14.5  (5.23 %)2022 Q1
12/31/2021-15.3 -26  (-69.93 %)2021 Q4
9/30/2021-14.79 -15.5  (-4.8 %)2021 Q3
1
2
3
4
5
...
8

Windtree Therapeutics shareholders

%
Name
Stocks
Change
Date
0.11492 % Deerfield Management Company, L.P.33,79333,7938/5/2024
0.06176 % Duvvuri (Krishna)18,16118,16110/9/2023
0.05803 % Lincoln Park Capital, LLC17,06508/5/2024
0.02050 % Fraser (Craig E)6,0295,43110/8/2024
0.01303 % Panacea Venture Healthcare Fund I LP3,83205/17/2023
0.00512 % Tower Research Capital LLC1,5061,5066/30/2024
0.00193 % Mcandrew (Jamie)5695698/24/2023
0.00110 % Huang (James Z)32405/17/2023
0.00044 % Strobeck (Mark)1281288/23/2023
0.00020 % Simonson (Steven G M.D.)6008/5/2024
1
2
3
4
...
5

Windtree Therapeutics Executives and Management Board

Mr. Eric Curtis(55)
Windtree Therapeutics Chief Operating Officer, Senior Vice President
Compensation 1.76 M
Mr. Craig Fraser(58)
Windtree Therapeutics Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial Officer (since 2016)
Compensation 940,910
Dr. Steven Simonson(64)
Windtree Therapeutics Senior Vice President, Chief Medical Officer
Compensation 600,011
Mr. Daniel Geffken(66)
Windtree Therapeutics Independent Director
Compensation 65,344
Dr. Robert Scott(69)
Windtree Therapeutics Independent Director
Compensation 60,344
1
2

Most common questions regarding Windtree Therapeutics

What values and corporate philosophy does Windtree Therapeutics represent?

Windtree Therapeutics Inc represents a commitment to advancing the field of respiratory medicine through innovative solutions. The company strives for excellence, driving breakthroughs in the treatment of respiratory diseases. With a focus on developing therapeutics for neonatal and pediatric patients, Windtree Therapeutics aims to improve the quality of life for these vulnerable populations. By leveraging their expertise and research capabilities, the company aims to revolutionize respiratory care and bring about positive change in the healthcare industry. Windtree Therapeutics remains dedicated to making a lasting impact and improving patient outcomes through their values of innovation, scientific rigor, and patient-centricity.

In which countries and regions is Windtree Therapeutics primarily present?

Windtree Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Windtree Therapeutics achieved?

Some significant milestones achieved by Windtree Therapeutics Inc include the successful completion of a Phase 2 clinical trial for their lead product candidate, AEROSURF®, which showed positive results in treating respiratory distress syndrome in premature infants. Additionally, the company secured funding through multiple grants and partnerships to support further research and development initiatives. Windtree Therapeutics Inc also advanced their pipeline of potential therapies and received approvals for various patents related to their innovative technologies. With their continued dedication to improving patient care and advancing medical solutions, Windtree Therapeutics Inc has positioned itself as a leading player in the biopharmaceutical industry.

What is the history and background of the company Windtree Therapeutics?

Windtree Therapeutics Inc, formerly known as Discovery Laboratories Inc, is a biotechnology company specializing in developing and commercializing products for respiratory diseases and other healthcare issues. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. Windtree focuses on developing novel therapies using its proprietary technology platform, which includes advanced lipids and synthetic lung surfactant formulations. With a strong commitment to improving patient outcomes, Windtree Therapeutics aims to address unmet medical needs in respiratory care. The company's dedication to innovation and expertise in the field have positioned it as a leader in the development of respiratory therapies.

Who are the main competitors of Windtree Therapeutics in the market?

The main competitors of Windtree Therapeutics Inc in the market are companies like AstraZeneca, GlaxoSmithKline, and Novartis.

In which industries is Windtree Therapeutics primarily active?

Windtree Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Windtree Therapeutics?

The business model of Windtree Therapeutics Inc is focused on developing and commercializing innovative therapeutics for respiratory diseases and other indications. Windtree Therapeutics Inc is dedicated to addressing unmet needs in patient care by leveraging its proprietary technology platform. With a focus on improving treatments for respiratory conditions, the company aims to advance its product pipeline to provide better outcomes for patients. Windtree Therapeutics Inc's commitment to innovation, strategic partnerships, and research and development drives its business model and enables the company to deliver novel therapeutic solutions in the healthcare industry.

What is the P/E ratio of Windtree Therapeutics 2024?

The Windtree Therapeutics P/E ratio is -0.04.

What is the P/S ratio of Windtree Therapeutics 2024?

The Windtree Therapeutics P/S ratio is 0.

What is the Quality Investing of Windtree Therapeutics?

The Quality Investing for Windtree Therapeutics is 2/10.

What is the revenue of Windtree Therapeutics 2024?

The revenue cannot currently be calculated for Windtree Therapeutics.

How high is the profit of Windtree Therapeutics 2024?

The expected Windtree Therapeutics profit is -71.39 M USD.

What is the business model of Windtree Therapeutics

Windtree Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for respiratory diseases and lung disorders. The company utilizes an innovative technology platform called Aerosolized KL4 Surfactant to develop aerosolized medications that can directly target and treat affected areas in the lungs.

What is the Windtree Therapeutics dividend?

Windtree Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Windtree Therapeutics pay dividends?

The dividend cannot currently be calculated for Windtree Therapeutics or the company does not pay out a dividend.

What is the Windtree Therapeutics ISIN?

The ISIN of Windtree Therapeutics is US97382D3035.

What is the Windtree Therapeutics WKN?

The WKN of Windtree Therapeutics is A2P3ZQ.

What is the Windtree Therapeutics ticker?

The ticker of Windtree Therapeutics is WINT.

How much dividend does Windtree Therapeutics pay?

Over the past 12 months, Windtree Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Windtree Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Windtree Therapeutics?

The current dividend yield of Windtree Therapeutics is .

When does Windtree Therapeutics pay dividends?

Windtree Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Windtree Therapeutics?

Windtree Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Windtree Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Windtree Therapeutics located?

Windtree Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Windtree Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Windtree Therapeutics from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Windtree Therapeutics pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Windtree Therapeutics in the year 2023?

In the year 2023, Windtree Therapeutics distributed 0 USD as dividends.

In which currency does Windtree Therapeutics pay out the dividend?

The dividends of Windtree Therapeutics are distributed in USD.

All fundamentals about Windtree Therapeutics

Our stock analysis for Windtree Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Windtree Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.